Wolbachia Mosquitoes & Dengue: Fighting Disease During COVID-19
- The number of dengue cases worldwide has increased dramatically since 2000, according to the World Health Institution.
- Katie Anders, Director of Impact assessment at WMP, highlighted the importance of the results.
- According to Anders, the study's design accounted for factors that previous trials struggled with, such as natural fluctuations in dengue dynamics.
Combat the global surge in dengue fever! Discover how Wolbachia mosquitoes are emerging as a powerful tool in the fight against this debilitating disease, notably during the challenges of COVID-19. A recent trial in Yogyakarta, Indonesia, revealed that Wolbachia mosquitoes slashed dengue cases by an extraordinary 77%. The World Mosquito Program (WMP) is now scaling up these interventions in major cities across Colombia, Brazil, Mexico, and Indonesia, aiming to reach over 75 million people in the next five years. Dr. katie Anders from WMP details the innovative strategies, including drone deployment.News directory 3 notes the impact of the pandemic, which has strained health systems. What’s next in the battle against dengue? Explore the WMP’s expansion!
Wolbachia Mosquitoes Offer Hope for Dengue Control
Updated May 28, 2025
The number of dengue cases worldwide has increased dramatically since 2000, according to the World Health Institution. Though, a promising solution is emerging: Wolbachia mosquitoes. These mosquitoes, infected with Wolbachia bacteria, demonstrated a 77% reduction in dengue cases during a trial conducted by the World Mosquito program (WMP) in Yogyakarta, Indonesia.
Dr. Katie Anders, Director of Impact assessment at WMP, highlighted the importance of the results. The Yogyakarta trial divided the city into communities, with some receiving the Wolbachia mosquitoes while others served as a control. The study confirmed dengue cases in laboratories,adding scientific rigor.
According to Anders, the study’s design accounted for factors that previous trials struggled with, such as natural fluctuations in dengue dynamics. She also noted that the results are likely a conservative estimate due to movement of peopel and mosquitoes between communities.
The WMP is now prioritizing large cities with a high burden of dengue, expanding its interventions in countries including Colombia, Brazil, Mexico, and Indonesia. “In cities seeing tens of thousands of dengue cases,Wolbachia offers a huge potential benefit,” Anders said.
The program aims to reach over 75 million people in the next five years, a meaningful increase from the 5 million reached to date. A second randomized controlled trial is planned for Belo Horizonte, Brazil, later this year.
The WMP is shifting its focus toward scaled implementation and cost-effectiveness. Innovations include producing large quantities of high-quality mosquito eggs,optimizing the supply chain,involving the community more directly,and using drones for mosquito release.
The COVID-19 pandemic has presented challenges, impacting data gathering and community-based activities. Anders noted that Singapore,Thailand,and Malaysia have experienced significant dengue outbreaks alongside COVID-19,potentially overwhelming health systems.
“Singapore is facing its largest dengue epidemic on record this year. Thailand and Malaysia have also had big years. And thay’re also dealing with COVID-19. Dengue and COVID-19 combined could overwhelm health systems.”
What’s next
Despite the challenges posed by COVID-19, dengue-endemic countries recognize the ongoing need for effective control measures. The WMP continues to engage with prospective partners, and the results from the Yogyakarta trial strengthen its position as it expands operations in the coming years.